<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716413</url>
  </required_header>
  <id_info>
    <org_study_id>2021-12649</org_study_id>
    <nct_id>NCT04716413</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment</brief_title>
  <official_title>Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment Who Are Undergoing Ambulatory Surgery- a Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this case, series, the investigators are testing the hypothesis that sublingual sufentanil&#xD;
      (Dsuvia) will improve postoperative pain management in the PACU in ambulatory surgery&#xD;
      patients taking Suboxone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morphine equivalence</measure>
    <time_frame>During day of surgery</time_frame>
    <description>Evaluate the total amount of morphine equivalence (MME) in the perioperative period (defined as combined total opioid used intra-op and in the PACU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to fit to discharge from the PACU</measure>
    <time_frame>During stay in PACU, up until discharge from PACU</time_frame>
    <description>How much time did subject take to become considered 'fit to discharge?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>additional opioids</measure>
    <time_frame>PACU stay to 24 hours post hospital discharge</time_frame>
    <description>Look at how many additional opioids subject needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to take the first additional opioid</measure>
    <time_frame>24 hours post hospital discharge</time_frame>
    <description>How soon did subject require an additional opioid?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events in the PACU</measure>
    <time_frame>During PACU stay, up until discharge from PACU</time_frame>
    <description>Make note of nausea, vomiting, itching, hypotension, dizziness that occur while in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events post discharge from PACU</measure>
    <time_frame>24 hours</time_frame>
    <description>Make note of nausea, vomiting, itching, hypotension, dizziness that occur within 24 hours after being discharged from PACU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL. If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be receive routine standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dsuvia</intervention_name>
    <description>Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age range 18-100 years&#xD;
&#xD;
               -  Currently taking Suboxone&#xD;
&#xD;
               -  ASA physical score 1-3&#xD;
&#xD;
               -  Able to provide a signed informed consent&#xD;
&#xD;
               -  General anesthesia (either endotracheal intubation or laryngeal mask airway)&#xD;
                  without the use of regional anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Known allergic reactions to Dsuvia and its excipients&#xD;
&#xD;
               -  Severe respiratory illness including exacerbation of asthma attack&#xD;
&#xD;
               -  Significant intraoperative hemodynamic instability&#xD;
&#xD;
               -  Use of Regional anesthesia techniques&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naum Shaparin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naum Shaparin, MD</last_name>
    <phone>718-920-2802</phone>
    <email>nshapari@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Singh Nair, PhD</last_name>
    <phone>718-920-5932</phone>
    <email>sinair@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naum Shaparin, MD</last_name>
      <phone>718-920-2802</phone>
      <email>nshapari@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine. Anesthesiology. 2017 Jun;126(6):1180-1186. doi: 10.1097/ALN.0000000000001633. Review.</citation>
    <PMID>28511196</PMID>
  </reference>
  <reference>
    <citation>Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011 Jan;106(1):32-51. doi: 10.1111/j.1360-0443.2010.03140.x. Epub 2010 Nov 4. Review.</citation>
    <PMID>21054613</PMID>
  </reference>
  <reference>
    <citation>Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005 Mar;29(3):297-326. Review.</citation>
    <PMID>15781180</PMID>
  </reference>
  <reference>
    <citation>Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006 Jan 17;144(2):127-34. Review. Erratum in: Ann Intern Med. 2006 Mar 21;144(6):460.</citation>
    <PMID>16418412</PMID>
  </reference>
  <reference>
    <citation>Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013 Jul;40(3):367-77. doi: 10.1007/s11414-013-9341-3.</citation>
    <PMID>23702611</PMID>
  </reference>
  <reference>
    <citation>Roberts DM, Meyer-Witting M. High-dose buprenorphine: perioperative precautions and management strategies. Anaesth Intensive Care. 2005 Feb;33(1):17-25. Review.</citation>
    <PMID>15957687</PMID>
  </reference>
  <reference>
    <citation>Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979 Feb;17(2):81-110. Review.</citation>
    <PMID>378645</PMID>
  </reference>
  <reference>
    <citation>Claxton AR, McGuire G, Chung F, Cruise C. Evaluation of morphine versus fentanyl for postoperative analgesia after ambulatory surgical procedures. Anesth Analg. 1997 Mar;84(3):509-14.</citation>
    <PMID>9052292</PMID>
  </reference>
  <reference>
    <citation>Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002 Jun;3(3):159-80.</citation>
    <PMID>14622770</PMID>
  </reference>
  <reference>
    <citation>Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, Geisslinger G, Lötsch J. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth. 2011 Sep;107(3):319-28. doi: 10.1093/bja/aer200. Epub 2011 Aug 5.</citation>
    <PMID>21841049</PMID>
  </reference>
  <reference>
    <citation>Minkowitz HS, Leiman D, Melson T, Singla N, DiDonato KP, Palmer PP. Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study. Pain Pract. 2017 Sep;17(7):848-858. doi: 10.1111/papr.12531. Epub 2017 Feb 10.</citation>
    <PMID>27781372</PMID>
  </reference>
  <reference>
    <citation>Jove M, Griffin DW, Minkowitz HS, Ben-David B, Evashenk MA, Palmer PP. Sufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty: A Randomized, Placebo-controlled Study. Anesthesiology. 2015 Aug;123(2):434-43. doi: 10.1097/ALN.0000000000000746.</citation>
    <PMID>26079801</PMID>
  </reference>
  <reference>
    <citation>Ringold FG, Minkowitz HS, Gan TJ, Aqua KA, Chiang YK, Evashenk MA, Palmer PP. Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: a randomized, placebo-controlled study. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):22-30. doi: 10.1097/AAP.0000000000000152.</citation>
    <PMID>25318408</PMID>
  </reference>
  <reference>
    <citation>W.M. Tvetenstrand CD, Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting., J Clin Anesth Pain Manag. 4 2.</citation>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dsuvia</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

